# Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation

Study · id `cardio:ct-nct07835581` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07835581](<https://clinicaltrials.gov/study/NCT07835581>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07835581

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 620 participants.

## Technical summary

Registry record NCT07835581. Randomized; no masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 620 participants (planned count; ClinicalTrials.gov record NCT07835581, source copy `cardio:ctgov-nct07835581-2026-09-30`, retrieved 2026-10-26)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07835581, source copy `cardio:ctgov-nct07835581-2026-09-30`, retrieved 2026-10-26)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT07835581, source copy `cardio:ctgov-nct07835581-2026-09-30`, retrieved 2026-10-26)
- Completion: 2033-03 (anticipated) (ClinicalTrials.gov record NCT07835581, source copy `cardio:ctgov-nct07835581-2026-09-30`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07835581-2026-09-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
- Acronym: LEGACY
- Condition: Kidney Transplant Rejection
- Intervention (Drug): Tegoprubart
- Intervention (Drug): Tacrolimus
- Lead sponsor: Eledon Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Eledon Pharmaceuticals (`cardio:org-eledon-pharmaceuticals`)

## Provenance

Content hash: d9f6322b6bcb0226d2e665e22ca0b6e4d16204bb57b3d9d906dadc18af6a0a9a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
